ARYx Therapeutics, Inc.
ARYX · OTC
12/31/2009 | 12/31/2008 | 12/31/2007 | 12/31/2006 | |
|---|---|---|---|---|
| Revenue | $0 | $20 | $4 | $5 |
| % Growth | -100% | 374.4% | -12.3% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $2 |
| Gross Profit | $0 | $19 | $4 | $3 |
| % Margin | – | 98.8% | 93.7% | 55.3% |
| R&D Expenses | $21 | $40 | $25 | $24 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $10 | $10 | $8 | $7 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $31 | $50 | $33 | $31 |
| Operating Income | -$31 | -$30 | -$29 | -$28 |
| % Margin | – | -154.2% | -692.6% | -596.9% |
| Other Income/Exp. Net | -$2 | -$1 | $1 | $1 |
| Pre-Tax Income | $0 | $0 | $0 | $0 |
| Tax Expense | $1 | $1 | -$1 | -$1 |
| Net Income | -$33 | -$31 | -$28 | -$27 |
| % Margin | – | -158.3% | -662.8% | -576.7% |
| EPS | -1.21 | -1.65 | -2.93 | -26.84 |
| % Growth | 26.7% | 43.7% | 89.1% | – |
| EPS Diluted | -1.21 | -1.65 | -2.93 | -26.84 |
| Weighted Avg Shares Out | 27 | 19 | 9 | 1 |
| Weighted Avg Shares Out Dil | 27 | 19 | 9 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $1 | $3 | $2 |
| Interest Expense | $2 | $2 | $1 | $1 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$30 | -$29 | -$28 | -$27 |
| % Margin | – | -148.7% | -662.9% | -577.5% |